Bristol-Myers Squibb Shares Face Setback Following Clinical Trial Halt
Published on 11/17/2025 at 07:04 | Redaktion boerse-global.de
Investors in Bristol-Myers Squibb encountered a significant market downturn as the pharmaceutical giant and its collaborator, Johnson & Johnson, terminated a pivotal late-stage trial for their experimental blood thinner, Milvexian. The decision to discontinue the Librexia-ACS study emerged after an interim analysis indicated the trial was unlikely to meet its primary objective, delivering a substantial blow to a project once viewed as a potential multi-billion dollar opportunity.
The financial markets responded swiftly to the clinical development. Even before formal trading commenced, Bristol-Myers Squibb’s stock value declined by more than 5%, ultimately closing the session with an approximate 4% loss. This downturn reflects heightened investor concern regarding the company’s developmental pipeline.
Analyst Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
